Kezar bags a $50M B round in wake of PhIa study; Bayer kicks back a partnered drug
→ Right on the heels of what it calls a successful Phase Ia study for its immunoproteasome inhibitor, South San Francisco-based Kezar Life Sciences has attracted a big syndicate for a $50 million B round. Cormorant Asset Management and Morningside Venture led the round, which includes new investors like Cowen Healthcare Investments, Pappas Ventures, Qiming Venture Partners and Bay City Capital. They were joined by existing investors EcoR1 Capital, Omega Funds, and Aju IB Investment. Kezar has now raised a total of $73 million since its inception in 2015.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.